

Sensimed AG appoints Patrick Berdoz as Chairman of the Board of Directors.

Lausanne, Switzerland, September 8th, 2010 – Following Sensimed’s recent Series B round of financing, Mr. Patrick Berdoz has been appointed as Chairman of the Board of Directors of Sensimed AG, a Swiss medical devices company. Sensimed, active in developing and commercializing innovating micro-technology for medical devices, has developed the SENSIMED Triggerfish[®], a revolutionary solution to monitor continuously fluctuations in intra-ocular pressure. Patrick Berdoz is taking over from Dr. Pierre Comte.

Dr. Pierre Comte took over the chairmanship of Sensimed AG on February 2008, following its Series A round of financing. Under the chairmanship of Dr. Comte, the company has achieved numerous significant milestones in its development: finalization of the development of the SENSIMED Triggerfish[®], industrialization of this product, implementation of ISO9001, CE marking and legal manufacturing for the SENSIMED Triggerfish[®], initial target commercialization of the product in selected centers throughout Europe, various post-marketing clinical trials in leading centers worldwide, strategic partnerships with key industry players such as ST microelectronics or Handok Pharmaceuticals, and recently an oversubscribed Series B financing round.

Patrick Berdoz received his MBA in Economics from HEG in Lausanne Switzerland in 1985. Following a short career in finance, Patrick became CEO (1986) and owner (1988) of Viso Medical, an intravenous therapy company located in Neuchâtel, Switzerland. His first major success came when he sold Viso Medical to a pharma company. In 1994 Patrick continued his career in the medical field, becoming the CEO and Chairman of the Board of Precimed, a major worldwide orthopedic manufacturer. While continuing his global leadership role, Patrick moved to the US in 1998 to establish Precimed, Inc. He made a few acquisitions from startups technologies to mature the company that he continued to develop. Patrick successfully sold Precimed in 2008 to Greatbatch (NYSE: GB) and is now leading a diverse group of start-up companies active in the Medical Device, Dental, Watch and Telecommunications industries.

The company will now focus on commercializing its SENSIMED Triggerfish[®] in broader markets including the U.S. and Asia, on obtaining regulatory approval in additional geographies, on reimbursement in selected countries, and on expanding significantly the scope of post-marketing application trials. The company will also be looking for additional strategic partnerships to support the commercialization of the device on a global scale.

Mr. Berdoz will be working with a strong board including institutional investor representatives Erich Schlick with Wellington Patrnrs, Patrick Scherrer with Vinci Capital/PME Renaissance, Michel Habib with Agate Medical Investments and Sonja Keppler with New Value AG. The team also includes Jean-Marc Wismer, CEO, and Matteo Leonardi, founder and CTO. The company is also working closely with various world-class industry and clinical experts.

Says Mr. Berdoz: "I'm very honored to become a part of Sensimed at this inflexion point in the development of the company. With the guidance of a great Board of Directors and the execution by a strong Management team, the next steps are going to be extremely interesting and exciting. Indeed Sensimed has a unique product that clearly improves the lives of patients and provides ground-breaking solutions for medical doctors, which makes Sensimed extraordinary and profoundly life-changing. It is a privilege to lead this Board".

Jean-Marc Wismer, CEO of the company: "The entrepreneurial experience of Patrick Berdoz is a strong asset for Sensimed and the management team is looking forward to a productive and complementary collaboration. With its recent round of financing, and the addition of strong competences both at the board level and in the management team, Sensimed is well armed to tackle its next milestones and the whole team is looking forward to exciting times".

About Sensimed AG

SENSIMED AG is a Swiss company with its principal focus on design, development and commercialization of integrated micro-systems for medical devices. SENSIMED AG is a spin-off of the well renowned Swiss Federal Institute of Technology (EPFL) and grows within a world-leading cluster for medical devices in the lake of Geneva area. SENSIMED AG has developed the SENSIMED Triggerfish®, a new patented, non-invasive solution that will significantly improve identification and treatment of glaucoma disease by monitoring intraocular pressure around the clock.

Contact details:

SENSIMED AG

Jean-Marc Wismer, CEO

Tel. +41 78 636-2951

Email: jean-marc_wismer@sensimed.ch

SENSIMED AG

Rue Centrale 6 • 1003 Lausanne • Switzerland

Tel. +41 21 311 9025 • Fax. +41 21 311 9027

www.sensimed.ch • info@sensimed.ch